-
1
-
-
8044254622
-
Identification of Shc docking site on Ret tyrosine kinase
-
Arighi E, Alberti L, Torriti F, Ghizzoni S, Rizzetti MG, Pelicci G, Pasini B, Bongarzone I, Piutti C, Pierotti MA et al. 1997 Identification of Shc docking site on Ret tyrosine kinase. Oncogene 14 773-782.
-
(1997)
Oncogene
, vol.14
, pp. 773-782
-
-
Arighi, E.1
Alberti, L.2
Torriti, F.3
Ghizzoni, S.4
Rizzetti, M.G.5
Pelicci, G.6
Pasini, B.7
Bongarzone, I.8
Piutti, C.9
Pierotti, M.A.10
-
2
-
-
0029893933
-
A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins
-
Asai N, Murakami H, Iwashita T & Takahashi M 1996 A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. Journal of Biological Chemistry 271 17644-17649.
-
(1996)
Journal of Biological Chemistry
, vol.271
, pp. 17644-17649
-
-
Asai, N.1
Murakami, H.2
Iwashita, T.3
Takahashi, M.4
-
3
-
-
9244251611
-
The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma
-
Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P et al. 1996 The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Molecular and Cellular Biology 16 2151-2163.
-
(1996)
Molecular and Cellular Biology
, vol.16
, pp. 2151-2163
-
-
Borrello, M.G.1
Alberti, L.2
Arighi, E.3
Bongarzone, I.4
Battistini, C.5
Bardelli, A.6
Pasini, B.7
Piutti, C.8
Rizzetti, M.G.9
Mondellini, P.10
-
4
-
-
2942638038
-
17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels
-
Braga-Basaria M, Hardy E, Gottfried R, Burman KD, Saji M & Ringel MD 2004 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. Journal of Clinical Endocrinology and Metabolism 89 2982-2988.
-
(2004)
Journal of Clinical Endocrinology and Metabolism
, vol.89
, pp. 2982-2988
-
-
Braga-Basaria, M.1
Hardy, E.2
Gottfried, R.3
Burman, K.D.4
Saji, M.5
Ringel, M.D.6
-
5
-
-
0030615230
-
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia
-
Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S & Bishop JM 1997 A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. PNAS 94 2551-2556.
-
(1997)
PNAS
, vol.94
, pp. 2551-2556
-
-
Brown, D.1
Kogan, S.2
Lagasse, E.3
Weissman, I.4
Alcalay, M.5
Pelicci, P.G.6
Atwater, S.7
Bishop, J.M.8
-
6
-
-
0037153375
-
The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation
-
Buckwalter TL, Venkateswaran A, Lavender M, La Perle KM, Cho JY, Robinson ML & Jhiang SM 2002 The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Oncogene 21 8166-8172.
-
(2002)
Oncogene
, vol.21
, pp. 8166-8172
-
-
Buckwalter, T.L.1
Venkateswaran, A.2
Lavender, M.3
La Perle, K.M.4
Cho, J.Y.5
Robinson, M.L.6
Jhiang, S.M.7
-
7
-
-
0037115405
-
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
-
Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M 2002a ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 62 7284-7290.
-
(2002)
Cancer Research
, vol.62
, pp. 7284-7290
-
-
Carlomagno, F.1
Vitagliano, D.2
Guida, T.3
Ciardiello, F.4
Tortora, G.5
Vecchio, G.6
Ryan, A.J.7
Fontanini, G.8
Fusco, A.9
Santoro, M.10
-
8
-
-
0036171234
-
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes
-
Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A & Santoro M 2002b The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Research 62 1077-1082.
-
(2002)
Cancer Research
, vol.62
, pp. 1077-1082
-
-
Carlomagno, F.1
Vitagliano, D.2
Guida, T.3
Napolitano, M.4
Vecchio, G.5
Fusco, A.6
Gazit, A.7
Levitzki, A.8
Santoro, M.9
-
9
-
-
0038697810
-
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)
-
Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A & Santoro M 2003 Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). Journal of Clinical Endocrinology and Metabolism 88 1897-1902.
-
(2003)
Journal of Clinical Endocrinology and Metabolism
, vol.88
, pp. 1897-1902
-
-
Carlomagno, F.1
Vitagliano, D.2
Guida, T.3
Basolo, F.4
Castellone, M.D.5
Melillo, R.M.6
Fusco, A.7
Santoro, M.8
-
10
-
-
4444273158
-
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
-
Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M & Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23 6056-6063.
-
(2004)
Oncogene
, vol.23
, pp. 6056-6063
-
-
Carlomagno, F.1
Guida, T.2
Anaganti, S.3
Vecchio, G.4
Fusco, A.5
Ryan, A.J.6
Billaud, M.7
Santoro, M.8
-
11
-
-
0038664387
-
BRAF mutation in papillary thyroid carcinoma
-
Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW & Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute 95 625-627.
-
(2003)
Journal of the National Cancer Institute
, vol.95
, pp. 625-627
-
-
Cohen, Y.1
Xing, M.2
Mambo, E.3
Guo, Z.4
Wu, G.5
Trink, B.6
Beller, U.7
Westra, W.H.8
Ladenson, P.W.9
Sidransky, D.10
-
12
-
-
0035209830
-
Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization
-
Corvi R, Martinez-Alfaro M, Harach HR, Zini M, Papotti M & Romeo G 2001 Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization. Laboratory Investigation 81 1639-1645.
-
(2001)
Laboratory Investigation
, vol.81
, pp. 1639-1645
-
-
Corvi, R.1
Martinez-Alfaro, M.2
Harach, H.R.3
Zini, M.4
Papotti, M.5
Romeo, G.6
-
13
-
-
0037392444
-
Issues and progress with protein kinase inhibitors for cancer treatment
-
Dancey J & Sausville EA 2003 Issues and progress with protein kinase inhibitors for cancer treatment. Nature Reviews. Drug Discovery 2 296-313.
-
(2003)
Nature Reviews. Drug Discovery
, vol.2
, pp. 296-313
-
-
Dancey, J.1
Sausville, E.A.2
-
14
-
-
0028104204
-
The ins and outs of Raf kinases
-
Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J & Rapp UR 1994 The ins and outs of Raf kinases. Trends in Biochemical Sciences 19 474-480.
-
(1994)
Trends in Biochemical Sciences
, vol.19
, pp. 474-480
-
-
Daum, G.1
Eisenmann-Tappe, I.2
Fries, H.W.3
Troppmair, J.4
Rapp, U.R.5
-
15
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417 949-954.
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
-
16
-
-
0034660859
-
Tyrosine 1062 of RETMEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival
-
De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN & Santoro M 2000 Tyrosine 1062 of RETMEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Research 60 3727-3731.
-
(2000)
Cancer Research
, vol.60
, pp. 3727-3731
-
-
De Vita, G.1
Melillo, R.M.2
Carlomagno, F.3
Visconti, R.4
Castellone, M.D.5
Bellacosa, A.6
Billaud, M.7
Fusco, A.8
Tsichlis, P.N.9
Santoro, M.10
-
17
-
-
1842735328
-
Oncogenic B-Raf mutations: Crystal clear at last
-
Dhillon AS & Kolch W 2004 Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 5 303-304.
-
(2004)
Cancer Cell
, vol.5
, pp. 303-304
-
-
Dhillon, A.S.1
Kolch, W.2
-
18
-
-
0031924319
-
Shc and Enigma are both required for mitogenic signaling by Ret/ptc2
-
Durick K, Gill GN & Taylor SS 1998 Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Molecular and Cellular Biology 18 2298-2308.
-
(1998)
Molecular and Cellular Biology
, vol.18
, pp. 2298-2308
-
-
Durick, K.1
Gill, G.N.2
Taylor, S.S.3
-
19
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R & Talpaz M 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine 344 1038-1042.
-
(2001)
New England Journal of Medicine
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Reese, S.F.5
Ford, J.M.6
Capdeville, R.7
Talpaz, M.8
-
20
-
-
0033890197
-
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia
-
European APL group
-
Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, Sanz M, Link H, Maloisel F, Gardin C et al. 2000 Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 14 1371-1377.
-
(2000)
Leukemia
, vol.14
, pp. 1371-1377
-
-
Fenaux, P.1
Chevret, S.2
Guerci, A.3
Fegueux, N.4
Dombret, H.5
Thomas, X.6
Sanz, M.7
Link, H.8
Maloisel, F.9
Gardin, C.10
-
21
-
-
0142135475
-
BRAF mutations in papillary carcinomas of the thyroid
-
Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K & Takenoshita S 2003 BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22 6455-6457.
-
(2003)
Oncogene
, vol.22
, pp. 6455-6457
-
-
Fukushima, T.1
Suzuki, S.2
Mashiko, M.3
Ohtake, T.4
Endo, Y.5
Takebayashi, Y.6
Sekikawa, K.7
Hagiwara, K.8
Takenoshita, S.9
-
23
-
-
0034254249
-
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
-
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA & Zigler AJ 2000 Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 925-932.
-
(2000)
Blood
, vol.96
, pp. 925-932
-
-
Heinrich, M.C.1
Griffith, D.J.2
Druker, B.J.3
Wait, C.L.4
Ott, K.A.5
Zigler, A.J.6
-
24
-
-
0036850514
-
Molecular and chromosomal mechanisms of resistance to imanitib (STI571) therapy
-
Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U et al. 2002 Molecular and chromosomal mechanisms of resistance to imanitib (STI571) therapy. Leukemia 16 2190-2196.
-
(2002)
Leukemia
, vol.16
, pp. 2190-2196
-
-
Hochhaus, A.1
Kreil, S.2
Corbin, A.S.3
La Rosee, P.4
Muller, M.C.5
Lahaye, T.6
Hanfstein, B.7
Schoch, C.8
Cross, N.C.9
Berger, U.10
-
25
-
-
0027305591
-
In vitro irradiation is able to cause RET oncogene rearrangement
-
Ito T, Seyama T, Iwamoto KS, Hayashi T, Mizuno T, Tsuyama N, Dohi K, Nakamura N & Akiyama M 1993 In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Research 53 2940-2943.
-
(1993)
Cancer Research
, vol.53
, pp. 2940-2943
-
-
Ito, T.1
Seyama, T.2
Iwamoto, K.S.3
Hayashi, T.4
Mizuno, T.5
Tsuyama, N.6
Dohi, K.7
Nakamura, N.8
Akiyama, M.9
-
26
-
-
0029671246
-
Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas
-
Jhiang SM, Sagartz JE, Tong Q, Parker-Thomburg J, Capen CC, Cho JY, Xing S & Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137 375-378.
-
(1996)
Endocrinology
, vol.137
, pp. 375-378
-
-
Jhiang, S.M.1
Sagartz, J.E.2
Tong, Q.3
Parker-Thomburg, J.4
Capen, C.C.5
Cho, J.Y.6
Xing, S.7
Ledent, C.8
-
27
-
-
0035810148
-
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
-
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B et al. 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New England Journal of Medicine 344 1052-1056.
-
(2001)
New England Journal of Medicine
, vol.344
, pp. 1052-1056
-
-
Joensuu, H.1
Roberts, P.J.2
Sarlomo-Rikala, M.3
Andersson, L.C.4
Tervahartiala, P.5
Tuveson, D.6
Silberman, S.7
Capdeville, R.8
Dimitrijevic, S.9
Druker, B.10
-
28
-
-
4344584872
-
B-RAF is a therapeutic target in melanoma
-
Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ et al. 2004 B-RAF is a therapeutic target in melanoma. Oncogene 23 6292-6298.
-
(2004)
Oncogene
, vol.23
, pp. 6292-6298
-
-
Karasarides, M.1
Chiloeches, A.2
Hayward, R.3
Niculescu-Duvaz, D.4
Scanlon, I.5
Friedlos, F.6
Ogilvie, L.7
Hedley, D.8
Martin, J.9
Marshall, C.J.10
-
29
-
-
4043110591
-
Experts call for smarter approach to targeted therapies
-
Katsnelson A 2004 Experts call for smarter approach to targeted therapies. Nature Medicine 10 764.
-
(2004)
Nature Medicine
, vol.10
, pp. 764
-
-
Katsnelson, A.1
-
30
-
-
0037379904
-
High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
-
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457.
-
(2003)
Cancer Research
, vol.63
, pp. 1454-1457
-
-
Kimura, E.T.1
Nikiforova, M.N.2
Zhu, Z.3
Knauf, J.A.4
Nikiforov, Y.E.5
Fagin, J.A.6
-
31
-
-
0042303810
-
RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase
-
Knauf JA, Kuroda H, Basu S & Fagin JA 2003 RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22 4406-4412.
-
(2003)
Oncogene
, vol.22
, pp. 4406-4412
-
-
Knauf, J.A.1
Kuroda, H.2
Basu, S.3
Fagin, J.A.4
-
32
-
-
0033989107
-
Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative
-
Lanzi C, Cassinelli G, Pensa T, Cassinis M, Gambetta RA, Borrello MG, Menta E, Pierotti MA & Zunino F 2000 Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. International Journal of Cancer 85 384-390.
-
(2000)
International Journal of Cancer
, vol.85
, pp. 384-390
-
-
Lanzi, C.1
Cassinelli, G.2
Pensa, T.3
Cassinis, M.4
Gambetta, R.A.5
Borrello, M.G.6
Menta, E.7
Pierotti, M.A.8
Zunino, F.9
-
33
-
-
0041867947
-
Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1
-
Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, Zanchi C, Yamamoto M & Zunino F 2003 Inactivation of Ret /Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cellular and Molecular Life Sciences 60 1449-1459.
-
(2003)
Cellular and Molecular Life Sciences
, vol.60
, pp. 1449-1459
-
-
Lanzi, C.1
Cassinelli, G.2
Cuccuru, G.3
Zaffaroni, N.4
Supino, R.5
Vignati, S.6
Zanchi, C.7
Yamamoto, M.8
Zunino, F.9
-
35
-
-
0034967978
-
Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade
-
Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J & Lax I 2001 Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Molecular and Cellular Biology 21 4177-4187.
-
(2001)
Molecular and Cellular Biology
, vol.21
, pp. 4177-4187
-
-
Melillo, R.M.1
Santoro, M.2
Ong, S.H.3
Billaud, M.4
Fusco, A.5
Hadari, Y.R.6
Schlessinger, J.7
Lax, I.8
-
36
-
-
0030881411
-
Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis
-
Mizuno T, Kyoizumi S, Suzuki T, Iwamoto KS & Seyama T 1997 Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 15 1455-1460.
-
(1997)
Oncogene
, vol.15
, pp. 1455-1460
-
-
Mizuno, T.1
Kyoizumi, S.2
Suzuki, T.3
Iwamoto, K.S.4
Seyama, T.5
-
37
-
-
0028862490
-
Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: A novel C-terminus for RET
-
Myers SM, Eng C, Ponder BA & Mulligan LM 1995 Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 11 2039-2045.
-
(1995)
Oncogene
, vol.11
, pp. 2039-2045
-
-
Myers, S.M.1
Eng, C.2
Ponder, B.A.3
Mulligan, L.M.4
-
38
-
-
0141453014
-
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers
-
Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397.
-
(2003)
Journal of Clinical Endocrinology and Metabolism
, vol.88
, pp. 4393-4397
-
-
Namba, H.1
Nakashima, M.2
Hayashi, T.3
Hayashida, N.4
Maeda, S.5
Rogounovitch, T.I.6
Ohtsuru, A.7
Saenko, V.A.8
Kanematsu, T.9
Yamashita, S.10
-
39
-
-
0033524002
-
Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas
-
Nikiforov YE, Koshoffer A, Nikiforova M, Stringer J & Fagin JA 1999 Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 18 6330-6334.
-
(1999)
Oncogene
, vol.18
, pp. 6330-6334
-
-
Nikiforov, Y.E.1
Koshoffer, A.2
Nikiforova, M.3
Stringer, J.4
Fagin, J.A.5
-
40
-
-
0034613291
-
Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells
-
Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA & Nikiforov YE 2000 Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science ]290 138-141.
-
(2000)
Science
, vol.290
, pp. 138-141
-
-
Nikiforova, M.N.1
Stringer, J.R.2
Blough, R.3
Medvedovic, M.4
Fagin, J.A.5
Nikiforov, Y.E.6
-
41
-
-
10744222003
-
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas
-
Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404.
-
(2003)
Journal of Clinical Endocrinology and Metabolism
, vol.88
, pp. 5399-5404
-
-
Nikiforova, M.N.1
Kimura, E.T.2
Gandhi, M.3
Biddinger, P.W.4
Knauf, J.A.5
Basolo, F.6
Zhu, Z.7
Giannini, R.8
Salvatore, G.9
Fusco, A.10
-
42
-
-
0034762203
-
The Raf/MEK/ERK pathway: New concepts of activation
-
Peyssonnaux C & Eychene A 2001 The Raf/MEK/ERK pathway: new concepts of activation. Biology of the Cell 93 53-62.
-
(2001)
Biology of the Cell
, vol.93
, pp. 53-62
-
-
Peyssonnaux, C.1
Eychene, A.2
-
43
-
-
0037228055
-
High frequency of BRAF mutations in nevi
-
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J et al. 2003 High frequency of BRAF mutations in nevi. Nature Genetics 33 19-20.
-
(2003)
Nature Genetics
, vol.33
, pp. 19-20
-
-
Pollock, P.M.1
Harper, U.L.2
Hansen, K.S.3
Yudt, L.M.4
Stark, M.5
Robbins, C.M.6
Moses, T.Y.7
Hostetter, G.8
Wagner, U.9
Kakareka, J.10
-
44
-
-
3643067689
-
The RET/PTC3 oncogene: Metastatic solid-type papillary carcinomas in murine thyroids
-
Powell DJJ, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A et al. 1998 The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Research 58 5523-5528.
-
(1998)
Cancer Research
, vol.58
, pp. 5523-5528
-
-
Powell, D.J.J.1
Russell, J.2
Nibu, K.3
Li, G.4
Rhee, E.5
Liao, M.6
Goldstein, M.7
Keane, W.M.8
Santoro, M.9
Fusco, A.10
-
45
-
-
9244255770
-
Development of thyroid papillary carcinomas secondary to tissue-specific expression ofthe RET/PTC1 oncogene in transgenic mice
-
Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G et al. 1996 Development of thyroid papillary carcinomas secondary to tissue-specific expression ofthe RET/PTC1 oncogene in transgenic mice. Oncogene 12 1821-1826.
-
(1996)
Oncogene
, vol.12
, pp. 1821-1826
-
-
Santoro, M.1
Chiappetta, G.2
Cerrato, A.3
Salvatore, D.4
Zhang, L.5
Manzo, G.6
Picone, A.7
Portella, G.8
Santelli, G.9
Vecchio, G.10
-
46
-
-
0036295515
-
Molecular mechanisms of RET activation in human cancer
-
Santoro M, Melillo RM, Carlomagno F, Fusco A & Vecchio G 2002 Molecular mechanisms of RET activation in human cancer. Annals of the New York Academy of Sciences 963 116-121.
-
(2002)
Annals of the New York Academy of Sciences
, vol.963
, pp. 116-121
-
-
Santoro, M.1
Melillo, R.M.2
Carlomagno, F.3
Fusco, A.4
Vecchio, G.5
-
47
-
-
0034603172
-
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway
-
Segouffin-Cariou C & Billaud M 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. Journal of Biological Chemistry 275 3568-3576.
-
(2000)
Journal of Biological Chemistry
, vol.275
, pp. 3568-3576
-
-
Segouffin-Cariou, C.1
Billaud, M.2
-
48
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J & Sawyers CL 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 117-125.
-
(2002)
Cancer Cell
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
Gorre, M.E.4
Paquette, R.L.5
Kuriyan, J.6
Sawyers, C.L.7
-
49
-
-
0141502211
-
Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation
-
Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, McMahon M & McCubrey JA 2003 Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17 1765-1782.
-
(2003)
Leukemia
, vol.17
, pp. 1765-1782
-
-
Shelton, J.G.1
Moye, P.W.2
Steelman, L.S.3
Blalock, W.L.4
Lee, J.T.5
Franklin, R.A.6
McMahon, M.7
McCubrey, J.A.8
-
50
-
-
0043170833
-
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
-
Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 4578-4580.
-
(2003)
Oncogene
, vol.22
, pp. 4578-4580
-
-
Soares, P.1
Trovisco, V.2
Rocha, A.S.3
Lima, J.4
Castro, P.5
Preto, A.6
Maximo, V.7
Botelho, T.8
Seruca, R.9
Sobrinho-Simoes, M.10
-
51
-
-
0141592764
-
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth
-
Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW & Nelkin BD 2003 CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Research 63 5559-5563.
-
(2003)
Cancer Research
, vol.63
, pp. 5559-5563
-
-
Strock, C.J.1
Park, J.I.2
Rosen, M.3
Dionne, C.4
Ruggeri, B.5
Jones-Bolin, S.6
Denmeade, S.R.7
Ball, D.W.8
Nelkin, B.D.9
-
52
-
-
0031792561
-
Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia
-
Sugg SL, Ezzat S, Rosen IB, Freeman JL & Asa SL 1998 Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. Journal of Clinical Endocrinology and Metabolism 83 4116-4122.
-
(1998)
Journal of Clinical Endocrinology and Metabolism
, vol.83
, pp. 4116-4122
-
-
Sugg, S.L.1
Ezzat, S.2
Rosen, I.B.3
Freeman, J.L.4
Asa, S.L.5
-
53
-
-
1142287286
-
BRAF mutations are associated with some histological types of papillary thyroid carcinoma
-
Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guin XM & Sobrinho-Simoes M 2004 BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology 202 247-251.
-
(2004)
Journal of Pathology
, vol.202
, pp. 247-251
-
-
Trovisco, V.1
Vieira de Castro, I.2
Soares, P.3
Maximo, V.4
Silva, P.5
Magalhaes, J.6
Abrosimov, A.7
Guin, X.M.8
Sobrinho-Simoes, M.9
-
54
-
-
0028825189
-
RET/PTC oncogene activation is an early event in thyroid carcinogenesis
-
Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M & Fusco A 1995 RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11 1207-1210.
-
(1995)
Oncogene
, vol.11
, pp. 1207-1210
-
-
Viglietto, G.1
Chiappetta, G.2
Martinez-Tello, F.J.3
Fukunaga, F.H.4
Tallini, G.5
Rigopoulou, D.6
Visconti, R.7
Mastro, A.8
Santoro, M.9
Fusco, A.10
-
55
-
-
12144289677
-
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
-
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D et al. 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 855-867.
-
(2004)
Cell
, vol.116
, pp. 855-867
-
-
Wan, P.T.1
Garnett, M.J.2
Roe, S.M.3
Lee, S.4
Niculescu-Duvaz, D.5
Good, V.M.6
Jones, C.M.7
Marshall, C.J.8
Springer, C.J.9
Barford, D.10
-
56
-
-
0041589377
-
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines
-
Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research 63 4561-4567.
-
(2003)
Cancer Research
, vol.63
, pp. 4561-4567
-
-
Xu, X.1
Quiros, R.M.2
Gattuso, P.3
Ain, K.B.4
Prinz, R.A.5
|